📊 SLDB Key Takeaways
Is Solid Biosciences Inc. (SLDB) a Good Investment?
Solid Biosciences is a clinical-stage biotech company burning $47.2M annually on declining revenue ($8.1M, -40.6% YoY), resulting in extreme operating losses and negative margins exceeding -700%. While the company maintains exceptional liquidity with $297.1M cash and zero debt, the accelerating cash burn combined with revenue contraction creates a finite runway (~6 years) with no demonstrated path to profitability.
Solid Biosciences Inc. Key Strengths (SLDB)
- Exceptional balance sheet with $297.1M cash and 13.1x current ratio providing multi-year operational runway
- Zero debt burden (Debt/Equity 0.0x) eliminates financial risk from leverage
- Diluted EPS loss narrowing 35% YoY despite net loss, indicating some operational improvement trajectory
SLDB Stock Risks: Solid Biosciences Inc. Investment Risks
- Revenue collapsing 40.6% YoY signals commercial challenges or failed product launches, contradicting growth requirements
- Operating cash burn of $47.2M annually on $8.1M revenue base ($708M loss per $1M revenue) is unsustainable without major catalyst
- Extreme negative margins (-708% operating, -701% net) with no visibility to profitability inflection within current business model
- Finite cash runway (~6.3 years at current burn rate) creates existential dependency on clinical success and funding
Key Metrics to Watch
- Revenue trajectory reversal - critical indicator of product commercialization success or failure
- Quarterly cash burn rate - any acceleration would materially reduce runway window
- Clinical trial progress and regulatory milestones - binary events determining long-term viability
- Cash position relative to operating cash flow - early warning indicator of funding crisis timeline
Solid Biosciences Inc. (SLDB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.10x current ratio provides a solid financial cushion.
SLDB Profit Margin, ROE & Profitability Analysis
SLDB vs Healthcare Sector: How Solid Biosciences Inc. Compares
How Solid Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Solid Biosciences Inc. Stock Overvalued? SLDB Valuation Analysis 2026
Based on fundamental analysis, Solid Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Solid Biosciences Inc. Balance Sheet: SLDB Debt, Cash & Liquidity
SLDB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Solid Biosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.06 indicates the company is currently unprofitable.
SLDB Revenue Growth, EPS Growth & YoY Performance
SLDB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | N/A | -$21.2M | N/A |
| Q2 2020 | N/A | -$19.0M | N/A |
| Q1 2020 | N/A | -$26.7M | N/A |
| Q3 2019 | N/A | -$19.0M | N/A |
| Q2 2019 | N/A | -$18.0M | N/A |
| Q1 2019 | N/A | -$15.9M | N/A |
| Q3 2018 | N/A | -$13.5M | N/A |
| Q2 2018 | N/A | -$11.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Solid Biosciences Inc. Dividends, Buybacks & Capital Allocation
SLDB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Solid Biosciences Inc. (CIK: 0001707502)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLDB
What is the AI rating for SLDB?
Solid Biosciences Inc. (SLDB) has an AI grade of C with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLDB's key strengths?
Claude: Exceptional balance sheet with $297.1M cash and 13.1x current ratio providing multi-year operational runway. Zero debt burden (Debt/Equity 0.0x) eliminates financial risk from leverage.
What are the risks of investing in SLDB?
Claude: Revenue collapsing 40.6% YoY signals commercial challenges or failed product launches, contradicting growth requirements. Operating cash burn of $47.2M annually on $8.1M revenue base ($708M loss per $1M revenue) is unsustainable without major catalyst.
What is SLDB's revenue and growth?
Solid Biosciences Inc. reported revenue of $8.1M.
Does SLDB pay dividends?
Solid Biosciences Inc. does not currently pay dividends.
Where can I find SLDB SEC filings?
Official SEC filings for Solid Biosciences Inc. (CIK: 0001707502) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLDB's EPS?
Solid Biosciences Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SLDB's fundamental grade?
Based on our AI fundamental analysis in May 2026, Solid Biosciences Inc. has a C grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SLDB stock overvalued or undervalued?
Valuation metrics for SLDB: ROE of -15.2% (sector avg: 15%), net margin of -701.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SLDB's AI grade for 2026?
Our dual AI analysis gives Solid Biosciences Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLDB's free cash flow?
Solid Biosciences Inc.'s operating cash flow is $-47.2M, with capital expenditures of $165.0K. FCF margin is -585.6%.
How does SLDB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -701.0% (avg: 12%), ROE -15.2% (avg: 15%), current ratio 13.10 (avg: 2).